Literature DB >> 1645591

Functional analysis of E2-mediated repression of the HPV18 P105 promoter.

F Thierry1, P M Howley.   

Abstract

Transcription of the transforming genes E6 and E7 of the human papillomavirus type 18 (HPV18) can be repressed by the product of the E2 open reading frame. Mutations were introduced in the cis-responsive elements upstream from the E6 and E7 transcriptional promoter, P105. The effect of these mutations in the absence or presence of E2 was examined in the human cervical carcinoma cell line C33, transfected with expression plasmids. In the presence of HPV18 E2, repression was relieved only when both of the two E2 binding motifs, immediately proximal to the P105 TATA box, were mutated. Mutation of a third E2 binding site, 110 nucleotides upstream of the TATA box, led to a slight but consistent activation in the presence of the full-length E2. Therefore, three E2 binding sites appear to be involved in the negative regulation of the P105 promoter by HPV18 E2. In the presence of the BPV1 E2 protein, only the E2 binding site most proximal to the promoter TATA box was involved in the P105 repression. The comparative analysis of the in vitro and in vivo properties of the human and bovine E2 proteins on the HPV18 P105 promoter provides new insights into the mechanism of transcriptional repression, which appears to involve steric hindrance at the site of transcriptional initiation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645591

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  75 in total

1.  The E8 domain confers a novel long-distance transcriptional repression activity on the E8E2C protein of high-risk human papillomavirus type 31.

Authors:  F Stubenrauch; T Zobel; T Iftner
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Cooperative activation of human papillomavirus type 8 gene expression by the E2 protein and the cellular coactivator p300.

Authors:  Andreas Müller; Andreas Ritzkowsky; Gertrud Steger
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Two AP1 sites binding JunB are essential for human papillomavirus type 18 transcription in keratinocytes.

Authors:  F Thierry; G Spyrou; M Yaniv; P Howley
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  Interaction of the papillomavirus E8--E2C protein with the cellular CHD6 protein contributes to transcriptional repression.

Authors:  Jasmin Fertey; Ingo Ammermann; Michael Winkler; Reinhard Stöger; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

5.  Biologic properties and nucleotide sequence analysis of human papillomavirus type 51.

Authors:  O Lungu; C P Crum; S Silverstein
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

6.  Brd4 is required for e2-mediated transcriptional activation but not genome partitioning of all papillomaviruses.

Authors:  M G McPhillips; J G Oliveira; J E Spindler; R Mitra; A A McBride
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator.

Authors:  Noor Gammoh; Helena Sterlinko Grm; Paola Massimi; Lawrence Banks
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

8.  Brd4-independent transcriptional repression function of the papillomavirus e2 proteins.

Authors:  Michal-Ruth Schweiger; Matthias Ottinger; Jianxin You; Peter M Howley
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

9.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

10.  Human papillomavirus type 16 status in cervical carcinoma cell DNA assayed by multiplex PCR.

Authors:  Krzysztof Lukaszuk; Joanna Liss; Izabela Wozniak; Janusz Emerich; Czesław Wójcikowski
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.